SPCC: Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond - OncoDaily SPCC: Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond / biomarker testing, cancer, Cancer research, cancer therapy, cancer treatment

SPCC: Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond

oncodaily.com/blog/227603

#BiomarkerTesting #Cancer #CancerResearch #CancerTherapy #CancerTreatmentAdvancements #ClinicalCharacteristics #HR+/HER2-MBC #MetastaticBreastCancer #OncoDaily #Health #Medicine

#MedSky🧪#IDSky #PublicHealth #Clinical_ID
#Splenicabscess 2ndary to #COVID19 : A case report and literature review
This case introduces the #clinicalcharacteristics of secondary #splenicabscess caused by #COVID19 / #Postcovid from the aspects of etiology, disease course , clinical manifestations,